Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs.

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Gastroenterology

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) were developed as safer alternatives to steroids.
• Cyclooxygenase (COX)-2 inhibitors (coxibs) emerged, offering potentially reduced gastrointestinal risks compared to traditional NSAIDs.
• Market withdrawal of rofecoxib highlighted significant cardiovascular risks associated with coxibs, shifting clinical focus.

Purpose of the Study:

• To explain how coxibs influenced the understanding of NSAID cardiovascular safety.
• To discuss the implications of COX-2 inhibition on cardiovascular risk.
• To review the current landscape of NSAID safety, considering both gastrointestinal and cardiovascular aspects.

Main Methods:

• Review of clinical practice and market trends concerning NSAIDs and coxibs.
• Analysis of the relationship between COX-2 specificity and cardiovascular risk.
• Examination of current recommendations for NSAID selection.

Main Results:

• All NSAIDs, including traditional and coxibs, are associated with cardiovascular risks.
• COX-2 activity/specificity is a factor in cardiovascular risk, but not the sole determinant.
• Naproxen and ibuprofen show less COX-2 specificity than some traditional NSAIDs.

Conclusions:

• NSAIDs should be viewed as a single class regarding cardiovascular risk, distinct from aspirin.
• Clinicians must balance immediate gastrointestinal benefits against long-term cardiovascular risks.
• Ibuprofen and naproxen are preferred NSAIDs; coxibs are suitable for specific patient profiles with high GI risk and low CV risk.